RG 2133

Drug Profile

RG 2133

Alternative Names: RG2133; Triacetyluridine - Repligen; Uridine prodrug

Latest Information Update: 20 Feb 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Repligen
  • Developer Repligen Corporation
  • Class Antidepressants; Chemoprotectants; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Metabolic disorders

Highest Development Phases

  • Discontinued Metabolic disorders; Mood disorders; Parkinson's disease

Most Recent Events

  • 20 Feb 2007 Discontinued - Phase-I/II for Affective disorders in USA (PO)
  • 20 Feb 2007 Discontinued - Preclinical for Parkinson's disease in USA (PO)
  • 22 Nov 2004 Preclinical trials in Parkinson's disease in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top